Difference between revisions of "Estrogen receptor"
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
==Negative== | ==Negative== | ||
*[[Endocervical adenocarcinoma]]. | *[[Endocervical adenocarcinoma]].<ref name=pmid20335127>{{Cite journal | last1 = Hu | first1 = WW. | last2 = Tao | first2 = JH. | last3 = Li | first3 = GM. | last4 = Xu | first4 = X. | last5 = Yang | first5 = XM. | title = [Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas]. | journal = Nan Fang Yi Ke Da Xue Xue Bao | volume = 30 | issue = 3 | pages = 526-8, 531 | month = Mar | year = 2010 | doi = | PMID = 20335127 }}</ref> | ||
==See also== | ==See also== | ||
Revision as of 20:34, 23 June 2016
Estrogen receptor, abbreviated ER, is a common immunostain.
General
In the context of breast pathology it is a class II IHC test, as it is used for treatment decisions by itself.[1]
Positive
- Breast carcinoma - most.
- Ductal carcinoma in situ - most.
- Invasive lobular carcinoma - all.
- Invasive ductal carcinoma of the breast - most.
- Endometrial carcinomas.
Occasionally positive
- Lung adenocarcinoma - dependent on the ER subunit target - ERα ~1%, ERβ ~79%.[2]
Negative
See also
References
- ↑ Torlakovic, EE.; Riddell, R.; Banerjee, D.; El-Zimaity, H.; Pilavdzic, D.; Dawe, P.; Magliocco, A.; Barnes, P. et al. (Mar 2010). "Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests.". Am J Clin Pathol 133 (3): 354-65. doi:10.1309/AJCPDYZ1XMF4HJWK. PMID 20154273.
- ↑ Tanaka, K.; Shimizu, K.; Kakegawa, S.; Ohtaki, Y.; Nagashima, T.; Kaira, K.; Horiguchi, J.; Oyama, T. et al. (2016). "Prognostic significance of aromatase and estrogen receptor beta expression in EGFR wild-type lung adenocarcinoma.". Am J Transl Res 8 (1): 81-97. PMID 27069542.
- ↑ Hu, WW.; Tao, JH.; Li, GM.; Xu, X.; Yang, XM. (Mar 2010). "[Value of ER, VIM, CEA and p16 detection in the diagnosis and differential diagnosis of primary endocervical and endometrial adenocarcinomas].". Nan Fang Yi Ke Da Xue Xue Bao 30 (3): 526-8, 531. PMID 20335127.